Compare
Xenon Pharmaceuticals Inc. vs Adagene Inc. vs Bolt Biotherapeutics, Inc. vs Ovid Therapeutics Inc.
| Latest fiscal year | Xenon Pharmaceuticals Inc. XENE | Adagene Inc. ADAG | Bolt Biotherapeutics, Inc. BOLT | Ovid Therapeutics Inc. OVID |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $7.50M | $7.67M | $7.70M | $7.25M |
| Revenue growth (YoY) | n/a | n/m | +0.1% | n/m |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | -279.5% | -469.3% | -585.2% |
| Net margin | n/m | -229.6% | -433.7% | -240.1% |
| Net income | -$345.91M | -$17.61M | -$33.38M | -$17.41M |
| EPS (Diluted) | -$4.36 | -$0.30 | -$17.85 | n/a |
| Operating cash flow | -$279.12M | -$15.66M | -$39.85M | -$38.33M |
| Free cash flow | -$279.92M | -$15.67M | -$39.92M | -$38.33M |
| Cash & equivalents | $199.16M | $74.52M | $11.70M | $13.15M |
| Total assets | $633.16M | $78.26M | $56.75M | $150.93M |
| Total liabilities | $51.40M | $26.36M | $30.24M | $20.27M |
| Shareholders' equity | $581.76M | $35.35M | $26.50M | $130.66M |
| Return on year-end equity | -59.5% | -49.8% | -125.9% | -13.3% |
| Shares outstanding | 80.01M | 59.23M | 1.92M | 130.18M |
Revenue, most recent five fiscal years
| Fiscal year | Xenon Pharmaceuticals Inc. | Adagene Inc. | Bolt Biotherapeutics, Inc. | Ovid Therapeutics Inc. |
|---|---|---|---|---|
| Latest | $7.50M Ended 2025-12-31 | $7.67M Ended 2025-12-31 | $7.70M Ended 2025-12-31 | $7.25M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | $103.2K Ended 2024-12-31 | $7.69M Ended 2024-12-31 | $566.0K Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $18.11M Ended 2023-12-31 | $7.88M Ended 2023-12-31 | $392.0K Ended 2023-12-31 |
| 3 years earlier | $9.43M Ended 2022-12-31 | $9.29M Ended 2022-12-31 | $5.73M Ended 2022-12-31 | $1.50M Ended 2022-12-31 |
| 4 years earlier | $18.44M Ended 2021-12-31 | $10.18M Ended 2021-12-31 | $1.26M Ended 2021-12-31 | $208.38M Ended 2021-12-31 |